Multikinase inhibitors as a new approach in neovascular age-related macular degeneration (AMD) treatment: In vitro safety evaluations of axitinib, pazopanib and sorafenib for intraocular use;Multikinase-Inhibitoren als therapeutischer Ansatz bei neovaskulärer AMD: In-vitro-Evaluation der Sicherheit von Axitinib, Pazopanib und Sorafenib zur intraokularen Anwendung

Klinische Monatsblatter fur Augenheilkunde

Volumn 230, Issue 3, 2013, Pages 247-254

  Thiele, S ^a   Liegl, R G ^a   Konig S ^a   Siedlecki, J ^a   Langer, J ^a   Eibl, K ^a   Haritoglou, C ^a   Kampik, A ^a   Kernt, M ^a  

^a LUDWIG MAXIMILIANS UNIVERSITY   (Germany)

Author keywords

AMD; anti VEGF; multikinase inhibitors; ranibizumab; retina

Indexed keywords

AXITINIB; HYDROGEN PEROXIDE; PAZOPANIB; SORAFENIB;

ARTICLE; ASTROCYTE; BIOCOMPATIBILITY; CELL DEATH; CELL TYPE; CELL VIABILITY; CONCENTRATION RESPONSE; CORNEA ENDOTHELIUM; DRUG SAFETY; HUMAN; HUMAN CELL; LENS EPITHELIUM; NITROBLUE TETRAZOLIUM TEST; OPTIC NERVE; ORGAN CULTURE; OXIDATIVE STRESS; PHASE CONTRAST MICROSCOPY; PIGMENT EPITHELIUM; RETINA MACULA AGE RELATED DEGENERATION; RISK ASSESSMENT; TRABECULAR MESHWORK;

ANGIOGENESIS INHIBITORS; ASTROCYTES; CELL SURVIVAL; CORNEA; DOSE-RESPONSE RELATIONSHIP, DRUG; ENDOTHELIAL CELLS; ENDOTHELIUM, CORNEAL; HUMANS; IMIDAZOLES; INDAZOLES; LENS, CRYSTALLINE; MICROSCOPY, PHASE-CONTRAST; NIACINAMIDE; OPTIC DISK; ORGAN CULTURE TECHNIQUES; OXIDATIVE STRESS; PHENYLUREA COMPOUNDS; PROTEIN KINASE INHIBITORS; PYRIMIDINES; RETINAL PIGMENT EPITHELIUM; SULFONAMIDES; TRABECULAR MESHWORK; WET MACULAR DEGENERATION;

EID: 84875080378     PISSN: 00232165     EISSN: 14393999     Source Type: Journal    
DOI: 10.1055/s-0032-1328161     Document Type: Article

References (22)

1. Algvere P. V., Seregard S. Age-related maculopathy: pathogenetic features and new treatment modalities. Acta Ophthalmol Scand: 2002; 80 136 143 (Pubitemid 34406844)
2. Fine S. L., Berger J. W., Maguire M. G. et al. Age-related macular degeneration. N Engl J Med: 2000; 342 483 492 (Pubitemid 30100237)
3. Aiello L. P. Targeting intraocular neovascularization and edema-one drop at a time. N Engl J Med: 2008; 359 967 969
4. Regillo C. D., Brown D. M., Abraham P. et al. Randomized, double-masked, sham-controlled trial of ranibizumab for neovascular age-related macular degeneration: PIER Study year 1. Am J Ophthalmol: 2008; 145 239 248
5. Rosenfeld P. J., Brown D. M., Heier J. S. et al. Ranibizumab for neovascular age-related macular degeneration. N Engl J Med: 2006; 355 1419 1431 (Pubitemid 44511557)
6. Rosenfeld P. J., Fung A. E., Puliafito C. A. Optical coherence tomography findings after an intravitreal injection of bevacizumab (avastin) for macular edema from central retinal vein occlusion. Ophthalmic Surg Lasers Imaging: 2005; 36 336 339 (Pubitemid 41073113)
7. Gragoudas E. S., Adamis A. P., Cunningham E. T. jr. et al. Pegaptanib for neovascular age-related macular degeneration. N Engl J Med: 2004; 351 2805 2816 (Pubitemid 40051904)
8. Bukowski R. M. Pazopanib: a multikinase inhibitor with activity in advanced renal cell carcinoma. Expert Rev Anticancer Ther: 2010; 10 635 645
9. Wilhelm S. M., Adnane L., Newell P. et al. Preclinical overview of sorafenib, a multikinase inhibitor that targets both Raf and VEGF and PDGF receptor tyrosine kinase signaling. Mol Cancer Ther: 2008; 7 3129 3140
10. Diago T., Pulido J. S., Molina J. R. et al. Ranibizumab combined with low-dose sorafenib for exudative age-related macular degeneration. Mayo Clin Proc: 2008; 83 231 234 (Pubitemid 351303111)
11. Kernt M., Staehler M., Stief C. et al. Resolution of macular oedema in occult choroidal neovascularization under oral Sorafenib treatment. Acta Ophthalmol: 2008; 86 456 458
12. Kernt M., Liegl R. G., Rueping J. et al. Sorafenib protects human optic nerve head astrocytes from light-induced overexpression of vascular endothelial growth factor, platelet-derived growth factor, and placenta growth factor. Growth Factors: 2010; 28 211 220
13. Kernt M., Neubauer A. S., Liegl R. G. et al. Sorafenib prevents human retinal pigment epithelium cells from light-induced overexpression of VEGF, PDGF and PlGF. Br J Ophthalmol: 2010; 94 1533 1539
14. Kernt M., Thiele S., Hirneiss C. et al. [Cytoprotective and antiangiogenic effects of the multikinase inhibitor sorafenib on human retinal pigmentepithelium.]. Ophthalmologe: 2011; 108 445 451
15. Kernt M., Thiele S., Liegl R. G. et al. Axitinib modulates hypoxia-induced blood-retina barrier permeability and expression of growth factors. Growth Factors: 2012; 30 49 61
16. Kernt M., Neubauer A. S., De Kaspar H. M. et al. Intravitreal voriconazole: in vitro safety-profile for fungal endophthalmitis. Retina: 2009; 29 362 370
17. Kernt M., Neubauer A. S., Ulbig M. W. et al. In vitro safety of intravitreal moxifloxacin for endophthalmitis treatment. J Cataract Refract Surg: 2008; 34 480 488 (Pubitemid 351625603)
18. Freyberger H., Brocker M., Yakut H. et al. Increased levels of platelet-derived growth factor in vitreous fluid of patients with proliferative diabetic retinopathy. Exp Clin Endocrinol Diabetes: 2000; 108 106 109 (Pubitemid 30234973)
19. Grisanti S., Tatar O. The role of vascular endothelial growth factor and other endogenous interplayers in age-related macular degeneration. Prog Retin Eye Res: 2008; 27 372 390
20. Liu L., Cao Y., Chen C. et al. Sorafenib blocks the RAF/MEK/ERK pathway, inhibits tumor angiogenesis, and induces tumor cell apoptosis in hepatocellular carcinoma model PLC/PRF/5. Cancer Res: 2006; 66 11851 11858 (Pubitemid 46094197)
21. Takahashi H., Tamaki Y., Ishii N. et al. Identification of a novel vascular endothelial growth factor receptor 2 inhibitor and its effect for choroidal neovascularization in vivo. Curr Eye Res: 2008; 33 1002 1010
22. Takahashi K., Saishin Y., Saishin Y. et al. Suppression and regression of choroidal neovascularization by the multitargeted kinase inhibitor pazopanib. Arch Ophthalmol: 2009; 127 494 499